Pro-Opiomelanocortin (POMC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Pro-Opiomelanocortin (POMC) Deficiency, a rare condition, manifests as monogenic obesity with severe early-onset obesity, adrenal insufficiency, red hair, and pale skin due to mutations in the POMC gene. This gene encodes the proopiomelanocortin protein, expressed in skin components such as melanocytes, keratinocytes, and dermal microvascular endothelial cells. The inheritance pattern is autosomal recessive. Glucocorticoids, CRH, and ultraviolet radiation control POMC expression. It is a prohormone for adrenocorticotropic hormone (ACTH), a crucial player in the adrenocortical response to stress. Promoter methylation regulates POMC expression, while in ACTH-dependent Cushing's syndrome, the POMC gene is intrinsically activated. POMC consists of three segments: N-POMC (N-terminus), ACTH (middle), and β-LPH (C-terminus). Only about 50 cases of POMC deficiency have been documented in the medical literature.
Thelansis’s
“Pro-Opiomelanocortin (POMC) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2023 To 2033" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Pro-Opiomelanocortin
(POMC) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights of Pro-Opiomelanocortin
(POMC) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Pro-Opiomelanocortin
(POMC) Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Pro-Opiomelanocortin
(POMC), Pro-Opiomelanocortin (POMC) market outlook, Pro-Opiomelanocortin
(POMC) competitive landscape, Pro-Opiomelanocortin
(POMC) market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment